Thymidylate synthase inhibitor
Thymidylate synthase inhibitors are chemical agents which inhibit the enzyme thymidylate synthase and have potential as an anticancer chemotherapy. Five agents were in clinical trials in 2002: raltitrexed, pemetrexed, nolatrexed, ZD9331, and GS7904L.
- Raltitrexed, used for colorectal cancer since 1998
- Fluorouracil, used for colorectal cancer
- BGC 945
- Jackman, A.L.; Calvert, A.H. (1995). "Folate-based thymidylate synthase inhibitors as anticancer drugs". Annals of Oncology. 6 (9): 871–881. PMID 8624289.
- "Thymidylate synthase inhibitors as anticancer agents: from bench to bedside". Retrieved 2009-01-28.
- Papamichael, D. (1999). "The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status". Oncologist. 4 (6): 478–87. PMID 10631692.
- Gibbs, David D.; et al. (2005). "BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors". Cancer Research. 65 (24): 11721–11728. doi:10.1158/0008-5472.CAN-05-2034. PMID 16357184.
- Ricart AD, Berlin JD, Papadopoulos KP, et al. (December 2008). "Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors". Clin. Cancer Res. 14 (23): 7947–55. doi:10.1158/1078-0432.CCR-08-0864. PMID 19047127.
|This biochemistry article is a stub. You can help Wikipedia by expanding it.|
|This oncology article is a stub. You can help Wikipedia by expanding it.|